The company intends to use the funds to support future studies of lead program BCA101, currently in Phase 1/1b clinical development in head and neck cancer, and pipeline growth.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

245 Main St
Cambridge, MA 02142
USA

Phone

Undisclosed

Website

www.bicara.com

Email Address

[email protected]

Overview

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.

Profile

Social Media

Bicara Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Claire Mazumdar

Chief Financial Officer

Ivan Hyep

Chief Operating Officer

Ryan Cohlhepp

Browse more venture capital transactions:

Prev: 3/6/2023: Congruence Therapeutics venture capital transaction
Next: 3/6/2023: RangeForce venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary